Navigation Links
Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain
Date:5/23/2013

therapy of dermatological diseases," said Robert Booth .

Background

About Cathepsin S and VBY-036

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes proteolytic cleavage of membrane-bound fractalkine from the surface of neurons to release soluble fractalkine.  Fractalkine is a potent chemokine that stimulates the recruitment of inflammatory cells to the sites of neuronal damage and activates microglia.  Microglia are macrophage-like cells that are implicated as key drivers in the pathogenesis of chronic neuropathic pain syndromes.  In model systems, cathepsin S mediated microglial activation is essential in the development of pain.  The inhibition of cathepsin S results in a reduction in pain, as well as prevention of pain in preclinical models of chemotherapy-induced neuropathic pain and diabetic neuropathy.

VBY-036 is an optimized cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of cathepsin S.  It has picomolar inhibitory potency against the isolated cathepsin S enzyme and nanomolar activity in cellular assays.  VBY-036 is also highly selective against related human cathepsins as well as other enzymes, and sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker.  The compound has been tested in pre-clinical studies and is now entering the next phase - a phase 1 clinical trial in healthy human volunteers.  The VBY-036 program is a novel approach to the treatment of pain and may result in a safe and effective oral therapeutic for an important unmet medical need.  

About Virobay, Inc.

Founded in 2006, Virobay is a leader in the design, synthesis and development of small molecule inhibitors of cysteine proteases, a class of enzymes that are key mediators in a variety of diseases, including autoimmunity, neuropath
'/>"/>

SOURCE Virobay, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
2. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
3. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
4. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
5. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
6. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
7. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
8. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
9. Applied Genetics Initiates Commercial Operation
10. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
11. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development company committed ... announced that the United States Patent & Trademark Office ... month of August that are part of a standard ... patents are: , U.S.RE45,065 issued August ... and , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
(Date:8/31/2014)... August 31, 2014 2014 ... is a professional and in-depth research report ... basic Polyacrylamide information, including Polyacrylamide definition, classification, ... as industry overview. This research covers the ... well as global industry analysis covering macroeconomic ...
(Date:8/29/2014)... but one of the most promising technologies for future ... light (photons) instead of electrons. First, it is necessary ... photons and control their direction. Researchers around the world ... control, but now scientists at the Niels Bohr Institute ... emitted one at a time and in a particular ...
Breaking Biology Technology:United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 2International Polyacrylamide Industry & Copper Iodide Market Data Analysis Now Available at DeepResearchReports.com 3Breakthrough in light sources for new quantum technology 2
... AC Immune SA, a leader,in Alzheimer,s disease drug development, ... Immune as Technology Pioneer 2009 for its,accomplishments as an ... a deep impact on business and society. , ... that it has reached significant clinical,milestones in the development ...
... A 60-year-old,prostate cancer patient from Montpellier has become ... RapidArc(TM) technology from Varian Medical Systems,(NYSE: ... intensity modulated radiotherapy,(IMRT). Each of his treatments at ... city took just 75 seconds, several times faster ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it ... year 2009 on December 10, 2008 at 7:00 a.m. EST and ... at 11:30 a.m. EST on the same day. , ... results for the second quarter ended October 31, 2008 and will ...
Cached Biology Technology:Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... the University of Warwick in the UK and the ... Journal Early Human Development , has found that ... birth and the use of mechanical ventilation are key ... Mathematic abilities are crucial for lifelong academic attainment. Impairments ... Earlier studies of children who are born very preterm ...
(Date:9/2/2014)... the most ideal source of nutrition for infants ... in the evolution and civilizations of human beings. ... large number of bacterial species, including some opportunistic ... surprise to scientists and physicians. , Indeed, the ... the result of co-evolutionary and co-adaptive interactions between ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3
... on labor-intensive microscopic examination, using century-old cell-staining ... and may give false readings. , A ... Laboratories researcher Paul Gourley, has provided laboratory ... liver tumor cells at their earliest stages, ...
... Canadian Network for Vaccines and Immunotherapeutics, has announced,the ... well the thymus (an organ,located at the base ... a,functional abnormality of this organ in HIV-infected individuals. ... professor at,Université de Montréal, scientist at the CHUM ...
... used to synthesize plastic food containers has been ... of prostate cancer cell,potentially affecting the treatment efficacy ... published in the January 1 issue of Cancer,Research, ... to,exposure to the chemical BPA (bisophenol A), an ...
Cached Biology News:Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 2Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2